Response to "Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia".
Infect Dis Ther
; 12(1): 301-302, 2023 Jan.
Article
in En
| MEDLINE
| ID: mdl-36417164
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Infect Dis Ther
Year:
2023
Document type:
Article
Affiliation country:
Italia